

Genmab A/S Toldbodgade 33 1253 Copenhagen K Denmark Tel + 45 7020 2728 Fax + 45 7020 2729 CVR no. 2102 3884

Contact:

Helle Husted Sr. Director, Investor Relations T: +45 33 44 77 30 M: +45 25 27 47 13 E: hth@genmab.com

GENMAB TO PRESENT AT 7TH ANNUAL FORTIS BANK BIOTECHNOLOGY CONFERENCE

Summary: Genmab will present at the 7th Annual Fortis Bank Biotechnology Conference on April 25, 2007 in London.

Copenhagen, Denmark; April 24, 2007 – Genmab A/S (CSE: GEN) announced today its Chief Scientific Officer, Prof. Jan van de Winkel, will present at the 7th Annual Fortis Bank Biotechnology Conference in London on April 25 at 9:30AM local time. The one day conference is being held at the Four Seasons Hotel in London, United Kingdom. The conference will feature presentations from select European and US biotechnology companies.

Prof. van de Winkel's presentation will be accessible via live and archived webcast at Genmab's website <u>www.genmab.com</u>.

About Genmab A/S

Genmab A/S is a biotechnology company that creates and develops human antibodies for the treatment of life-threatening and debilitating diseases. Genmab has numerous products in development to treat cancer, infectious disease, rheumatoid arthritis and other inflammatory conditions, and intends to continue assembling a broad portfolio of new therapeutic products. In addition, Genmab has developed UniBodyTM, a new proprietary technology that creates a stable, smaller antibody format. Genmab has operations in Europe and the US. For more information about Genmab, visit <u>www.genmab.com</u>.

This press release contains forward looking statements. The words "believe", "expect", "anticipate", "intend" and "plan" and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with product discovery and development, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to the outcome cause out actual trials including unforeseen safety issues, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to the outcome cause output the substitution of the safety issues.

GENMAB TO PRESENT AT 7TH ANNUAL FORTIS BANK BIOTECHNOLOGY CONFERENCE

product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. Genmab is not under an obligation to up-date statements regarding the future following the publication of this release; nor to confirm such statements in relation to actual results, unless this is required by law.

Genmab[®]; the Y-shaped Genmab logo[®]; HuMax[®]; HuMax-CD4[®]; HuMax-EGFr[™]; HuMax-Inflam[™]; HuMax-CD20[™]; HuMax-TAC[™]; HuMax-HepC[™], HuMax-CD38[™]; HuMax-ZP3[™]; and UniBody[™] are all trademarks of Genmab A/S.

###